Bombesin

A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.

Also Known As:

Networked: 978 relevant articles (44 outcomes, 116 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schally, Andrew V: 33 articles (05/2014 - 03/2002)
2.	Reubi, Jean Claude: 17 articles (01/2015 - 04/2002)
3.	Halmos, Gabor: 16 articles (10/2012 - 10/2003)
4.	Schally, A V: 14 articles (05/2008 - 03/2000)
5.	Waser, Beatrice: 13 articles (08/2015 - 07/2002)
6.	Chen, Xiaoyuan: 13 articles (10/2013 - 08/2004)
7.	Maecke, Helmut R: 12 articles (08/2015 - 09/2004)
8.	Smith, Charles J: 11 articles (02/2015 - 03/2005)
9.	Hoffman, Timothy J: 11 articles (02/2015 - 05/2003)
10.	Nagy, Attila: 10 articles (01/2006 - 04/2003)

Related Diseases

1.	Neoplasms (Cancer) 12/15/1997 - "The biodistribution study showed that the tumor localization (14.9 +/- 8.2% injected dose/gram; ID/g) of [125I]-mIP-bombesin 2 days after administration of AdCMVGRPr was significantly greater than its localization in other organs (P < 0.003) and was significantly greater than in AcCMVLacZ- and saline-treated mice (P < 0.003). " 08/01/1997 - "Additionally, tumors transduced in vivo to express GRPr demonstrated significantly greater localization of [125I]-mIP-bombesin when compared with [125I]-Tyr4-bombesin." 06/01/2008 - "In these analogues is replaced one ([D-Phe12]BN, [Tyr4]BN, and [Lys3]BN) or two ([Tyr4,D-Phe12]BN, [D-Phe12,Leu14]BN, and [Leu13-(R)-Leu14]BN) amino acid residues within the peptide chain with a synthetic amino acid, creating antagonists to bombesin, which are useful in the treatment of cancer. " 01/01/2011 - "In contrast, conjugation to a bombesin analog lacking the receptor-binding domain failed to increase the cytotoxicity of MG2, suggesting that bombesin conjugation enhances the cytotoxicity of MG2 in cancer cells through improved binding. " 04/05/2010 - "Bombesin and its analogues show promise for the targeted delivery of radioactive and chemotherapeutic agents to a wide variety of solid tumors. "
2.	Prostatic Neoplasms (Prostate Cancer) 05/06/2013 - "Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer." 07/01/2010 - "A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues." 03/01/2015 - "The aim of this first-in-man study was to demonstrate the feasibility, safety, and tolerability, as well as provide dosimetric data and evaluate the imaging properties, of the bombesin analogue BAY 864367 for PET/CT in a small group of patients with primary and recurrent prostate cancer (PCa). " 01/01/2012 - "Scintigraphy is generally not the first choice treatment for prostate cancer, although successful studies using bombesin analog radiopeptides have been performed. " 02/01/2011 - "In the present study, we developed an (18)F-labeled bombesin analog, (18)F-BAY 86-4367, which is currently being clinically tested for use in PET of prostate cancer. "
3.	Adenocarcinoma 02/01/2014 - "There was a significant GRP receptor density gradient (P ≤ 0.005), increasing from normal prostate glands (mean relative optical density, ROD, of ¹²⁵I-Tyr⁴ -bombesin binding: 0.17) over atypical glands without increased MIB-1 labeling (0.28) and atypical glands with increased MIB-1 expression (0.44) to high grade PIN and adenocarcinoma (0.64 and 0.58, respectively). " 07/01/2006 - "We hypothesized that pancreatic ductal adenocarcinoma (PDAC) might be imaged with the inverse strategy, that is by the design of a nanoparticle-conjugate targeted to bombesin (BN) receptors present on normal acinar cells of the pancreas. " 04/01/2006 - "Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma." 11/15/1996 - "Bombesin may be involved as a growth factor in the development of pancreatic ductal adenocarcinoma in humans. " 09/01/1994 - "Bombesin inhibits growth of pancreatic ductal adenocarcinoma (H2T) in nude mice."
4.	Neoplasm Metastasis (Metastasis) 01/01/2002 - "In eight of the nine cases with pathological lymph node metastases, expression of MMP-9 and bombesin was also noted in metastatic sites. " 01/01/1985 - "Very high concentrations of bombesin were identified in these metastases." 03/01/2003 - "Multi-receptor tumour targeting using the combination of bombesin and NPY(Y(1)) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases." 11/01/2001 - "Increased bombesin expression was correlated with colorectal adenocarcinomas exhibiting poor histological grade and their liver metastases. " 01/01/2001 - "Bombesin significantly increased the incidence of peritoneal metastasis from gastric cancers through the activation of Rho protein."
5.	Duodenal Ulcer (Curling's Ulcer) 11/01/1985 - "Bombesin and G-17 dose responses in duodenal ulcer and controls." 03/01/1983 - "An increased parietal cell mass could explain the higher gastric acid response after bombesin infusion in our group of patients with duodenal ulcer." 01/01/1979 - "Bombesin was found to be a very potent stimulator of gastric acid secretion in patients with duodenal ulcer. " 11/01/1985 - "Serum gastrin with bombesin stimulation was significantly greater in duodenal ulcer (maximum 467 pg/ml) than in controls (153 pg/ml), while in seven of the DU group tested gastrin levels after a meal were not different from that seen in five of the normal controls. " 03/01/1993 - "The total net increase of somatostatin in the presence of bombesin was significantly less in duodenal ulcer patients (0.10 +/- 0.02 ng/mg wet w.) than in normal subjects (1.45 +/- 0.24 ng/mg wet w.) (p < 0.01). "

Related Drugs and Biologics

1.	Bombesin Receptors (Bombesin Receptor)
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)
3.	Gastrins
4.	Gastrin-Releasing Peptide
5.	Substance P
6.	Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)
7.	Adrenocorticotropic Hormone (ACTH)
8.	Peptides
9.	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
10.	Gonadotropin-Releasing Hormone (GnRH)

Related Therapies and Procedures

1.	Radiotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Intravenous Injections
4.	Drug Therapy (Chemotherapy)
5.	Total Parenteral Nutrition